Objective To observe the efficacy and adverse effects of pemetrexed combined Nedaplatin therapy advanced breast cancer. Methods Our hospital department oncology from January 2013 to May 2014, 42 cases advanced breast cancer patients were treated, randomly divided into observation group 22 cases and control group 20 cases, observation group received pemetrexed therapy combined nedaplatin the control group received gemcitabine plus nedaplatin therapy, respectively, after two courses of treatment, patients were observed effectiveness and adverse reactions. Results The effective rate of 40.91%group therapy, disease control rate was 77.27%, the control group was 40.00%effective disease control rate was 75.00%, efifciency and disease control rate showed no signiifcant difference between the two groups(P>0.05), the two groups were adverse drug reactions were neutropenia, red blood cells and hemoglobin reduction to reduce symptoms such as bone marrow suppression, as well as nausea, vomiting, hair loss, and liver and kidney dysfunction, the incidence of adverse drug reactions the two groups showed no statistically signiifcant(P>0.05). Conclusions Pemetrexed combined Nedaplatin safe and effective treatment of advanced breast cancer, worthy of promotion.%目的：观察培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效及其不良反应。方法选取我院肿瘤科2013年1月至2014年5月收治的晚期乳腺癌患者42例，随机分为观察组22例和对照组20例，观察组给予培美曲塞联合奈达铂治疗，对照组给予吉西他滨联合奈达铂治疗，分别治疗2个疗程后，观察两组患者治疗有效率及不良反应。结果观察组治疗有效率为40.91%，疾病控制率为77.27%，对照组治疗有效率为40.00%，疾病控制率为75.00%，两组治疗有效率和疾病控制率比较均无明显差异（P>0.05），两组患者药物不良反应主要为白细胞减少、红细胞减少和血红蛋白减少等骨髓抑制症状，以及恶心、呕吐、脱发和肝肾功能损害等，两组药物不良反应发生率比较差异无统计学意义（P>0.05）。结论培美曲塞联合奈达铂治疗晚期乳腺癌安全有效，值得临床推广。
展开▼
